WG
STLN

Winton Group’s Starling Oncology STLN Stock Holding History

Winton Group’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$102K Buy
+18,800
New +$79K ﹤0.01% 1088

Other funds holding STLN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JAIC
Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Winton Group's STLN Position: Q2 2026 in Review

Winton Group opened a new position in Starling Oncology (STLN) in Q2 2026: 18,800 shares worth $102K. The stake represents ﹤0.01% of the portfolio and ranks #1088 among its holdings.

120 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

  • Winton Group held 18,800 shares of Starling Oncology worth $102K as of Q2 2026.
  • Starling Oncology was a new Winton Group position in Q2 2026.
  • Starling Oncology made up ﹤0.01% of Winton Group's portfolio in Q2 2026, its #1088 holding.
  • 120 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.